Press Releases

Date Title and Summary
Toggle Summary Accuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® System
MADISON, Wis. , Dec. 5, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact ® System in Japan beginning November 30, 2023 .
Toggle Summary Accuray Reports Fiscal 2024 First Quarter Financial Results
Company Achieves 8% Revenue Growth, Reiterates FY 2024 Guidance MADISON, Wis. , Nov. 7, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2024 ended September 30, 2023 .     First Quarter Fiscal 2024 Summary Net revenue of
Toggle Summary Accuray to Participate in the 14th Annual Jefferies London Healthcare Conference
MADISON, Wis. , Oct. 31, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the 14 th Annual Jefferies London Healthcare Conference. The management team is scheduled to participate in a presentation with moderated Q&A on Wednesday, November 15 th , 2023 at
Toggle Summary Accuray to Report First Quarter Fiscal 2024 Financial Results on November 7, 2023
MADISON, Wis. , Oct. 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2024, ended September 30, 2023 , during a conference call hosted by company management at 1:30 p.m. PT / 4:30 p.m. ET on November 7, 2023 .
Toggle Summary Accuray Announces Approval of the Tomo® C Radiation Treatment Delivery System by China's National Medical Products Administration
MADISON, Wis. , Oct. 3, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo ® C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration (NMPA).
Toggle Summary Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting
MADISON, Wis. , Oct. 2, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has a 510(k) pending for an online adaptive therapy option*, Cenos™, for its Radixact ® System. The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO ( American
Toggle Summary Accuray Opens New Global Training Center at Madison, WI Headquarters to Advance Radiotherapy Treatment Techniques Amid Growing Demand for Precision Cancer Care
Large classrooms and a hybrid, in-person/remote connection option will make it easier for more care providers to remain current on best practices and innovations in radiation therapy New center is part of the company's comprehensive education program which also includes on-site training, online
Toggle Summary Accuray to Host Investor Day at ASTRO on October 3, 2023
MADISON, Wis. , Sept. 14, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a discussion with analysts and investors on Tuesday, October 3, 2023 , in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting.
Toggle Summary Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market
The Radixact System, with the addition of the VitalHold functionality, provides clinicians with unmatched choice of radiation treatment delivery options in one device Treatment delivery versatility offers opportunities for personalization and makes exceptional quality care possible for more breast
Toggle Summary Accuray Reports Fourth Quarter and Fiscal 2023 Financial Results
8% Q4 revenue growth; Record shipments for FY23; Company issues guidance for FY24   MADISON, Wis. , Aug. 9, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2023, ended June 30, 2023 .       Fourth Quarter Fiscal 2023

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at and on the SEC's website at